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ABSTRACT
Ochratoxin A (OTA) is a natural mycotoxin, involved in the development of important human and animal diseases. In this work we have
studied the role of oxidative stress in the development of OTA nephrotoxicity and the effect of a new recombinant mitochondrial manganese
containing superoxide dismutase (rMnSOD) to prevent kidney damage induced by OTA. Blood pressure, glomerular ﬁltration rate and renal
histology were analyzed in control rats and in OTA treated rats. In addition, lipid peroxidation, catalase and superoxide dismutase productions
weremeasured. Our data showed that animals treatedwith OTA presented hypertension and reduction of glomerularﬁltration rate (GFR). These
effects are most probably related to an increase in the reactive oxygen species (ROS) productions. In fact, we have shown that treatment
with rMnSOD restored the levels of blood pressure and GFR simultaneously. Moreover, we have noted that OTA induced alteration on
glomerular and tubular degeneration and interstitial inﬁltrates and that use of rMnSOD combined with OTA prevent this renal histological
damage conﬁrming the potential therapeutic role in the treatment of rMnSOD OTA nephrotoxicity. J. Cell. Biochem. 117: 1352–1358,
2016. © 2015 Wiley Periodicals, Inc.
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Ochratoxin A (OTA), (R)-N-[(5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1H-2-benzopyran-7-yl) carbonyl] -L-
phenylalanine, is a natural mycotoxin produced by Aspergillus
and Penicillium species with important implications for animal
and human health [Krogh, 1976; Bozic et al., 1995]. It is found in
cereals, green coffee, dried fruits and meat products, resulting in
continuous exposure of the human and animal population to
OTA [Duarte et al., 2010]. For this reason several methods of
detoxiﬁcation in human and animal have been developed to
reduce the toxic effects of OTA [Creppy et al., 1998; Costa et al.,
2007; Fusi et al., 2010; Palabiyik et al., 2013].
OTA is absorbed from the gastrointestinal tract and in the small
intestine. It is distributed into the liver, muscle, fat and it is
accumulated into the kidney, where speciﬁc transporters may be
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involved in its cellular uptake [Costa et al., 2007]. OTA has been
shown to be nephrotoxic, hepatotoxic, teratogenic and immunotoxic
in several species of animals [Ribelin et al., 1978; Ringot et al., 2006;
Palabiyik et al., 2013] and in humans, it has been associated to
Balkan endemic nephropathy (BEN) [Boorman et al., 1992; Ringot
et al., 2006] although an exact mechanism of action is still unclear.
Several mechanisms of OTA toxicity have been proposed, as well as
the contribution of OTA to cause an imbalance between oxidant and
antioxidant parameters [Bui-Klimke and Wu, 2015]. It is interesting
to note that OTA increases the expression of nitric oxide synthase
[Wang et al., 2008] enzyme responsible for the production of nitric
oxide (NO) that is known to react with oxygen anion superoxide
(O2
) to form the pro-oxidant peroxynitrite. Moreover, it is well
demonstrated the contribution of OTA to increase the reactive
oxygen species (ROS) production, which may lead to oxidative stress
andmolecular damage that contribute to the pathogenesis of chronic
diseases [Castegnaro et al., 1998; Grollman and Jelakovic, 2007].
The mechanism of chronic nephrotoxic diseases has been
previously investigated by our research group. In particular, we
have demonstrated, in a rat animal model of hypertension induced
by cyclosporine, that the increase in ROS production, in particular
the O2
, was linked to a strong reduction of glomerularﬁltration rate
(GFR) [Ciarcia et al., 2015]. Since the reduction of antioxidants
expression has been shown to be related to an increase of oxidative
damage [Klaunig et al., 1998; Marin-Kuan et al., 2011] which
contribute to OTA toxicity.
Several antioxidants were tested, in vivo and in vitro, to
counteract the negative effects of ROS generated by OTA, such as
vitamin E [Fusi et al., 2010], catechins [Costa et al., 2007] and
licopene [Palabiyik et al., 2013] showing that they may partially
protect against OTA induced nephrotoxicity and oxidative stress. In
an our previous paper we have demonstrated the protective effect of
rMnSOD on renal function of CsA hypertensive rats after chronic
administration [Damiano et al., 2013].
In this study we have evaluated the effect of rMnSOD (a family
member of SOD codiﬁed by different genes localized exclusively in
the mitochondrial matrix [Okado-Matsumoto and Fridovich, 2001;
Ridnour et al., 2004;Mancini et al., 2006] and able to alter the growth
rate and invasiveness of cancer cells [Mancini et al., 2008] on in vivo
glomerular ﬁltration rate (GFR), on ROS production and in
histological damage in rat animal model treated for 14 days with
OTA. Moreover we have evaluated the relationship between OTA,
ROS production and the renal damage.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
The rats were obtained from Harlan Laboratories Srl (San Pietro al
Natisone, Udine, Italy); Ochratoxin A (OTA), Inulin and all the
reagents were obtained from Sigma–Aldrich (Milan, Italy), isoﬂur-
ane (Isotec 4, Ohmeda) by Albamedical (Naples, Italy) and rMnSOD
was obtained by Molecular Biology and Viral Oncology Department
of Experimental Oncology, Istituto Nazionale Tumori “Fondazione
G. Pascale”, IRCCS (Naples, Italy) [Mancini et al., 2006], Catalase and
SOD activity assays kits were purchased by Caymac Chemical
Company.
ETHICS STATEMENT
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by Italian Ministry of Health (Permit Number: 2015-
261-PR).
EXPERIMENTAL PROTOCOL
Experiments were performed on a total of 48 adult male Sprague
Dawley rats weighing 120–150 g. They were housed under constant
environmental conditions (temperature 22 °C and a 12 h light–dark
cycle). Animals were fed a standard diet; food and water were given
ad libitum. The rats, randomly divided into four groups, were treated
orally for 14 days as follows: Group 1 (Control group), 12 rats treated
with a corresponding amount of saline solution (including 10%
DMSO); Group 2 (rMnSOD group), 12 rats treated with rMnSOD
(10mg/kg); Group 3 (OTA group): 12 rats treated with OTA
(0,5mg/Kg bw) dissolved in 10% DMSO and then scaled to required
volume with corn oil; Group 4 (rMnSODþOTA), 12 rats treated with
rMnSOD (10mg /kg) plus OTA (0,5mg/Kg bw). The dose and length of
rMnSOD and OTA administration was chosen according to previous
experiments [Palabiyik et al., 2013; Damiano et al., 2013]. Blood
Pressure (BP) was recorded in anaesthetized rats, during the
clearance experiments, through the carotid artery using a blood
pressure recorder (Pressure Monitor BP-1, Word Precision
Instruments).
CLEARANCE OF INULIN
GFR wasmeasured at the end of the experimental treatment. The rats
were anaesthetized with 2% isoﬂurane (Isotec 4, Ohmeda), placed on
a thermo-regulated table (37 °C) and prepared for renal clearance
evaluation. In brief, the right carotid artery was catheterized to
monitor BP through a blood pressure recorder (BP1 by WPI) and to
take blood samples for inulin concentration measurements. The left
jugular vein was cannulated with polyethylene PE-50 tubing and
used for intravenous infusion via a syringe pump (Braun,
Melsungen) of 0.74mg/100 g bw/min of inulin from 10% saline
solution. The surgical procedure also included bladder catheteriza-
tion with PE-205 tubing. After a 60min equilibration period, theﬁrst
of four 30min urine collections began. Arterial blood samples
(100ml) were taken at the beginning and end of each collection
period. Inulin concentrations in plasma and urine were measured by
the colorimetric method and the absorbance was read at 550 nm
using a Glomax Multiþ detection system (Promega). The GFR was
calculated as: (perfusion rate perfusate inulin) / (plasma inulin)
where perfusate inulin and plasma inulin were the inulin concen-
trations in perfusate and plasma, respectively.
LIPID PEROXIDATION ASSAY
Lipid peroxidation as index of the oxidative stress was determined
by assaying the malondialdheyde (MDA) production bymeans of the
thiobarbituric acid (TBA) test by Esterbauer and Cheeseman [1990].
Kidney homogenates were obtained using a tissue homogenizer
Tissue Lyser LT (Quiagen) at 4 °C. The homogenates (1:10w/v) were
prepared by using a 100mM KCl buffer (7:00 pH) containing EDTA
0.3mM. Brieﬂy: 1ml of supernatant of renal tissue was mixed with
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0.5mL of cold 30% (w/v) trichloroacetic acid to precipitate proteins.
The precipitate was pelletted by ultracentrifugation and 1ml of the
supernatant was reacted with 1.3ml of 0.5% (w/v) TBA at 85 °C for
40min. In TBA test reaction, one molecule of MDA reacts with two
molecules of TBA with the production of a pink pigment having
maximal absorbance at 532–535nm. Therefore, after cooling, the
ﬂuorescence was read at an excitation of 536nm and an emission of
557nm wavelengths in a Glomax Multiþ detection system spec-
trophotoﬂuorimeter (Promega). The concentration of MDA was
calculated respect to a calibration curve (range: 0.5–2 pmoles/ml),
and results were expressed as pmoles of MDA/mg of proteins.
SOD ACTIVITY ASSAY
The assay for SOD activity involves inhibition of nitroblue
tetrazolium (NBT) reduction with xanthine-xanthine oxidase used
as a superoxide generator [Sun et al., 1988]. SOD activity was
determined by the sensitive SOD assay kit that utilizes a product a
water-soluble formazan dye upon reduction with superoxide anion
SOD activity with absorbance at 450 nm according to the
manufacturer0s instructions (Assay Kit Caymac Chemical Company).
Brieﬂy, 1ml of supernatant of renal tissue treated or not treated with
OTA and OTA in combinationwith rMnSODwasmixed. At the end of
incubation the supernatant was lysed and centrifuged at 14,000 g for
5min at 48 °C and on cytosol was determined cytosolic and
mitochondrial SOD activity. The starter of reaction by adding
Xanthine Solution. The absorbance readings every minute for
10min at room temperature. The rate of the reduction with a
superoxide anion is linearly related to the xanthine oxidase (XO)
activity, and is inhibited by SOD. The SOD activity was expressed as
units for milligrams of protein.
CAT ACTIVITY ASSAY
The colorimetric assay has been applied to evaluate catalase (CAT)
activity [Sinha, 1972]. The method is based on the principle that
dichromate in acetic acid is reduced to chromate acetate when heated
in the presence of H2O2, with the formation of perchromic acid as an
unstable intermediate. The chromic acetate thus produced was
measured colorimetrically and absorbance was read at 520 nm
according to the manufacturer0s instructions (Assay Kit Caymac
Chemical Company). Results were expressed as units for milligrams
of protein.
RENAL HISTOLOGY
The kidneys were removed and immediately ﬁxed by immersion in
Bouin0s ﬁxative (6–24 h). The specimens then were processed for
parafﬁn embedding in vacuum and cut at a thickness of 5–7mm.
Parafﬁn sections were stained by using haematoxylin-eosin in
order to study the renal histology. In addition, parafﬁn sections
were stained with Masson0s trichrome staining. The pictures were
taken at a 250 magniﬁcation (n¼ 5 section was examined) by
using a Leica DMRA2 microscope. The tissues were examined
without knowledge of the rat0s identity.
TOTAL PROTEIN ASSAY
Total proteins were determined by the method of Lowry et al.
[1951].
STATISTICAL ANALYSIS
All data are expressed as mean SD. Statistical analysis was
performed by one-way ANOVA followed by the unpaired t-test. A
value of P< 0.05 was considered statistically signiﬁcant.
RESULTS
BLOOD PRESSURE MEASUREMENT
As shown in the Figure 1, OTA signiﬁcantly increased BP, expressed
as mmHg, at 14 days of the treatment compared to control. In fact BP
values shifted from 94 6.10 (control) to 134 4.01mmHg (OTA)
(P< 0.05). However, the administration of rMnSOD in combination
with OTA restored this function from 134 4.01 (OTA) to 96 2.12
(rMnSODþOTA) mmHg (#P< 0.05). rMnSOD, utilized alone, did not
exert any change.
CLEARANCE OF INULIN
In the Figure 2 has shown the OTA effect on renal haemodynamics.
GFR, expressed asml/min 100g bw, wasmeasured bymeans of inulin
clearance. OTA treatment signiﬁcantly decreased GFR compared to
control animals. In fact GFR values shifted by from 0.98 0.02
(control) to 0.63 0.03 (OTA) ml/min (P< 0.05). The treatment with
rMnSOD in combinationwithOTA, exerteda goodprotectiononOTA-
induced GFR reduction. In fact the GFR values shifted from
0.63 0.03 (OTA) at 0.89 0.05 (rMnSODþOTA) ml/min
(#P< 0.05). rMnSOD utilized alone, did not exert any change on
glomerular function (0.85 0.07 respect to 0.98 0.02 control).
MDA LEVELS
n the Figure 3 has shown the OTA effects on lipid peroxidation
measured by the malondialdheyde (MDA) levels in rat kidney after
2 weeks of treatment. Renal MDA level, expressed as pmoles/mg
proteins, increased in OTA group respect to the control. In fact the
MDA values shifted from 440 11.21 (control) to 550 9.12 (OTA)
pmoles/mg proteins (P< 0.05). When rMnSOD was used in
association with OTA, we have observed a restore of this value
(550 9.12 (OTA) to 458 10.91 (OTAþ rMnSOD)) pmoles/mg
Fig. 1. Effects of OTA and rMnSOD used alone or in association on blood
pressure (BP) in rats treated for 2 weeks. OTA treatment signiﬁcantly increased
BP, while co-administration with rMnSOD partially restored this effect (values
mean SD; P< 0.05 vs. control group; #P< 0.05 vs. OTA group).
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proteins (#P< 0.05). rMnSOD utilized alone, did not exert any change
on lipid peroxidation (410 10.50 respect to 440 11.21 control).
SOD AND CAT ACTIVITY
As shown in the Figure 4, OTA and rMnSODþOTA groups they have
not changed total SOD activity compared to control. In fact the value
observed were of 21.24 8.11 (control) respect 28.56 9.21 (OTA)
and 25.84 11.11 (rMnSODþOTA) U/mg protein. rMnSOD, alone,
caused a signiﬁcant increase in SOD enzyme activity compared to
control group. In fact the SOD values shifted from 21.24 8.11
(control) to 49.94 13.09 (OTA) U/mg proein (P< 0.05). The OTA
and OTAþ rMnSOD did not exert any change on SOD activity.
Figure 5 shows the OTA effect on CAT activity. After 14 days of
treatmentwithOTAand rMnSODþOTAgroup they havenot changed
the CAT activity compared of control. In fact the value observed were
of 356 11.83 (control) respect 320 19.11 (OTA) and 331 19.09
(rMnSODþOTA) U/mg protein). The treatment with rMnSOD utilized
alone showed a signiﬁcant effect onCAT activity respect to control. In
fact the SOD values shifted from 356 11.83 (control group) to
480 21.11 (rMnSOD group) U/mg protein (P< 0.05).
HISTOPATHOLOGICAL EXAMINATION
The normal histological structure of the kidney was observed in
Figure 6. Section of the kidneys of control rats showed normal
appearance of glomerulus and renal tubules. On the other hand,
kidneys of rats treated with OTA for 14 days showed vacuolar
Fig. 2. Effects of OTA and rMnSOD used alone or in association on glomerular
ﬁltration rate (GFR) after 2 weeks of treatment. OTA treatment signiﬁcantly
decreased GFR, while co-administration with rMnSOD partially restored this
effect (values mean SD; P< 0.05 vs. control group; #P< 0.05 vs. OTA
group).
Fig. 3. Effects of OTA and rMnSOD used alone or in association on lipid
peroxidation measured by malondialdehyde (MDA) test in rat kidney after 2
weeks of treatment. OTA treatment signiﬁcantly increased MDA levels, while
co-administration with rMnSOD partially prevent this effect (values are
mean SD; P< 0.05 vs. control group; #P< 0.05 vs. OTA group).
Fig. 4. Effects of OTA and rMnSOD used alone or in association on SOD
enzymatic activity in rat kidney after 2 weeks of treatment. OTA treatment did
not show signiﬁcant change in SOD enzymatic activity respect to control. The
same result is obtained during co-administration with rMnSOD. rMnSOD used
alone showed a signiﬁcant change in SOD enzymatic activity respect to control
(values are mean SD; P< 0.05 vs. control group).
Fig. 5. Effects of OTA and rMnSOD used alone or in association on CAT
enzymatic activity in rat kidney after 2 weeks of treatment. OTA treatment did
not show signiﬁcant change in CAT enzymatic activity respect to control. The
same result is obtained during co-administration with rMnSOD (values are
mean SD, P< 0.05 vs. control group).
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degeneration of the tubular epithelium, reduction in the height of the
tubular epithelium,glomerular degeneration, presenceof cell debris in
the lumen of the tubule and interstitial inﬁltrates. These morphologi-
cal alterations were mainly located in the cortex and outer stripe of
outer medulla and they were common both in proximal and distal
tubules. The treatment of rats with rMnSOD and OTA in association
showed that tubular and glomerular degeneration was decreased.
rMnSOD treatment alone was not associated with signiﬁcant
morphological alteration, compared to control group.
In the Figure 7 has shown the OTA effect on interstitial ﬁbrosis
evaluated by Masson0s trichrome staining. OTA treatment induced a
more severe interstitial ﬁbrosis compared to control group.
Co-treatment of rMnSOD and OTA was associated with a decrease
of ﬁbrosis compared with the OTA group alone. rMnSOD treatment
alone was not associated with signiﬁcant interstitial ﬁbrosis
compared to control group.
DISCUSSION
OTA is involved in several animal and human diseases [Krogh, 1976;
Bozic et al., 1995]. In humans, it has been related to Balkan endemic
nephropathy and in animals, chronic exposure to OTA, produces a
well described nephropathy [Ribelin et al., 1978; Boorman et al.,
1992; Grollman et al., 2007; Bui-Klimke andWu, 2015]. In addiction,
chronic studies have shown a clear relationship between OTA
administration and the incidence of renal tumor in rat and in mouse
[Bendele et al., 1985; O0Brien et al., 2005].
The exact mechanism of OTA toxicity has not been yet
characterized. However, several studies have proposed the involve-
ment of reactive oxygen species to the nephrotoxicity induced by
OTA [Klaunig et al., 1998; Palabiyik et al., 2013]. In particular, the
gene expression proﬁles have revealed the involvement of the
antioxidant regulatory element (ARE) in their promoter region that is
recognized by the nuclear factor -erythroid 2 p45-related factor 2
(Nrf2) [Bendele et al., 1985]. Nrf2 involved in the expression and
induction of many genes, including genes for detoxiﬁcation and
antioxidant enzymes. Several studies [Hayes et al., 2000; Kensler
et al., 2007] have shown that the nephrotoxicity induced by OTA is
related to DNA damage induced by oxidative stress rather than a
direct interaction of OTA with the cellular DNA.
The present study was designed to investigate the relationship
between OTA exposure and ROS production in the development of
renal injury in rats treated for 2 weeks with oral injection of OTA and
the potential effect of the new recombination rMnSOD in the
treatment of OTA nephrotoxicity. We have measured the blood
pressure, the GFR alterations, the renal histology damage, the change
in lipid peroxidation, catalase and superoxide dismutase activities to
clarify the role of oxidative stress in the OTA nephropathy.
Our data, the ﬁrst reported so far, show that OTA induced
hypertension in treated rats. There are no data in the literature
explaining this effect, but it could be argued that this effect could be
to an increase of ROS productions. In fact, it has been demonstrated
in various experimental models of hypertension, that the increase of
blood pressure is linked to ROS increase and it is prevented by the
treatment with antioxidants [Gill and Wilcox, 2006; Palabiyik et al.,
2013]. In an our previous article we have shown that the use of
antioxidant apocynin in CsA hypertensive rats restored blood
pressure and levels of ROS [Ciarcia et al., 2015]. Here we have shown
that treatment with the new recombinant rMnSOD prevents
hypertension induced by OTA and, in addiction, restores lipid
peroxidation levels. Therefore, we could hypothesize that the
mechanism responsible of this result is linked to the rMnSOD ability
to scavenge most of the radical species. This property is probably
Fig. 6. Effects of OTA and rMnSOD used alone or in association on
morphological alteration in rat kidney after 2 weeks of treatment. rMnSOD
prevents OTA induced morphological alteration. Representative pictures of
haematoxylin and eosin staining from the renal cortex. OTA treatment showed
glomerular and tubular alteration. Co-treatment with rMnSOD is associated
with a partially restored of this histological alteration. Magniﬁcation ×250.
Fig. 7. Effects of OTA and rMnSOD used alone or in association on interstitial
ﬁbrosis evaluation in rat kidney after 2 weeks of treatment. rMnSOD prevents
OTA induced interstitial ﬁbrosis. Representative pictures ofMasson0s trichrome
staining from renal cortex. OTA treatment showed interstitial ﬁbrosis.
Co-treatment with rMnSOD is associated with a partially restored of this
histological alteration. Magniﬁcation ×250.
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related to the presence of a leader peptide that allows rMnSOD to
enter the cell thus preventing its degradation by circulating
proteases [Mancini et al., 2006], but further studies are needed.
It has been previously demonstrated that OTA induces also a
severe renal functional disorder with an abnormal creatinine and
BUN levels [Palabiyik et al., 2013]. Indeed, in our experiments, we
have found a severe decrease in the GFR measured by inulin
clearance, which is considered the gold standard method for the
measurement of renal function. Gekle and Silbernagl [1993] have
previously demonstrated in OTA treated rats that the decrease in GFR
was mediated by Angiotensin II (ANGII) increase. It is well
demonstrated that the increase in ANG II is accompanied by
oxidative stress and an increase in O2
 generation [Gill and Wilcox,
2006] reducing the bioavailability of the vasodilator nitric oxidase
and inducing a severe glomerular vasoconstriction with, conse-
quently, a reduction in GFR. Here we have shown that rMnSOD
restored the GFR. Therefore, although themechanism responsible for
the GFR reduction in OTA hypertensive rats has not been well
deﬁned, we hypothesized that the reduction of GFR is related to the
increase of ANG II and levels of O2
. It is possible that themechanism
responsible for these results on GFR is linked to the ability of
rMnSOD to scavenge most of the radical species, since it was
demonstrated that nephrotoxicity induced by OTA is linked to ROS
production and to an imbalance between oxidant/antioxidant
parameters [Schaaf et al., 2002].
Our data evidenced a severe histological damage as results of OTA
treatment. In fact, we have observed that OTA induced alteration on
tubular epithelium, glomerular degeneration and tubule and
interstitial inﬁltrates. Moreover, interstitial ﬁbrosis has been
observed. In agreement with our results, Palabiyik et al.
[2013] showed a tubular degenerative change such as epithelial
cell desquamation and detachment in OTA treated rats. Moreover,
Abdu et al. [2011] have found a global congestion in the renal tissue,
loss of demarcation between the cortex and medulla and pre-
apoptotic cells in rats treated for 28 days with OTA. Therefore, the
activation of damage and necrosis by OTA could be the cause of the
kidney damage and kidney failure.
Several mechanisms of OTA nephrotoxicity have been proposed,
such as the inhibition of protein synthesis, promotion of lipid
peroxidation, inhibition of mitochondrial respiration and DNA
damage [Bendele et al., 1985; Hayes et al., 2000; O0Brien et al., 2005;
Kensler et al., 2007].
Our data, according to the result of Palabiyik et al. [2013],
demonstrated that OTA did not modify SOD and CAT enzymatic
activity in treated rats. rMnSOD used alone increased both CAT and
SOD levels but did not modify such activity when used in association
with OTA. Thus, it could be hypothesized that the restoring potential
of rMnSOD on OTA nephrotoxicity is related to its direct scavenging
in activity on ROS, rather than to its modulation of cellular
enzymatic activities.
In this work we have showed that the hypertensive effect OTA, the
decrease in GFR and renal histological damage is due to the increase
of ROS production. In addition, rMnSOD is able to prevent in vivo the
deleterious effects of OTA and conﬁrmed its potential therapeutic
role in the treatment of OTA nephrotoxicity.
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